country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-141601

Copy Link Print Information

Telisotuzumab vedotin

Name: Telisotuzumab vedotin
Brand: MedChemExpress
SKU: HY-141601
Price: 290.00 USD
Availability: PreOrder

(Synonyms: ABBV-399)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1714088-51-3
Molecular Weight:145000 (average)

Speicherung:

-80°C, protect from light

Telisotuzumab vedotin Chemical Structure

CAS. Nr.: 1714088-51-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Telisotuzumab vedotin (ABBV-399) demonstrates potent cytotoxicity that is dependent on a threshold level of target expression and is not reliant on inhibiting MET signaling in tumor cell lines with high c-Met expression or MET amplification^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Telisotuzumab vedotin (ABBV-399) effectively inhibits tumor growth and overcomes resistance to small molecule MET inhibitors in xenograft models resistant to other c-Met inhibitors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Subcutaneous Cell-Line-Derived Xenograft

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1714088-51-3
Appearance Liquid
Molecular Weight 145000 (average)
Color Colorless to light yellow
SMILES

[Telisotuzumab vedotin]
Synonyms

ABBV-399
Versand

Shipping with dry ice.
Speicherung

-80°C, protect from light

Publications (3)

All In Vivo Efficacy StudyIn Vivo Imaging

Sort by:

Journal Impact Factor

Cell Rep Med

A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. [Abstract]

2026 Apr 21;7(4):102688. PMID: 41856115

Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]

Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Telisotuzumab vedotin, 10 nmol/kg)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm3) (n = 5∼7/group).

Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]

Bioluminescence imaging of mice with orthotopic pancreatic tumors treated with B6ADC or the combination of "SG and Telisotuzumab vedotin (10 nmol/kg)" for 28 days (n = 4/group).

Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]

Survival curves of mice treated with B6ADC or SG+Telisotuzumab vedotin (10 nmol/kg). Survival analysis was performed using the Kaplan-Meier method, and statistical significance was determined by the log rank (Mantel-Cox) test.
Mol Cancer Ther

HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles. [Abstract]

2025 Oct 30. PMID: 41166693
bioRxiv

2026 Jul 20.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. [Content Brief]

[2]. Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41(5): 1105-1115. [Content Brief]

[3]. Jieyi Wang, et al. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clin Cancer Res (2017) 23 (4): 992-1000.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Telisotuzumab vedotin

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Reinheit & Dokumentation
Verweise

1/16
1/16

Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]

Customer Validation
Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Telisotuzumab vedotin, 10 nmol/kg)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm3) (n = 5∼7/group).
1/16

Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]

Customer Validation
Bioluminescence imaging of mice with orthotopic pancreatic tumors treated with B6ADC or the combination of "SG and Telisotuzumab vedotin (10 nmol/kg)" for 28 days (n = 4/group).
1/16

Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]

Customer Validation
Survival curves of mice treated with B6ADC or SG+Telisotuzumab vedotin (10 nmol/kg). Survival analysis was performed using the Kaplan-Meier method, and statistical significance was determined by the log rank (Mantel-Cox) test.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Telisotuzumab vedotin

Publications Citing Use of MedChemExpress (MCE) Telisotuzumab vedotin